12 Month Price Forecast For ALKS
Distance to ALKS Price Forecasts
ALKS Price Momentum
🤔 Considering Alkermes (ALKS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 2:17 AM UTC
ALKS Analyst Ratings & Price Targets
Based on our analysis of 20 Wall Street analysts, ALKS has a consensus that is bullish. The median price target is $36.00, with forecasts ranging from $21.00 to $43.00. Currently, there are 9 Buy ratings, 4 Hold ratings, and 1 Sell ratings.
With ALKS currently trading at $30.21, the median price forecast suggests a 19.2% upside. The most optimistic forecast comes from Charles Duncan at Cantor Fitzgerald, projecting a 42.3% upside, while Cory Kasimov at JP Morgan provides the most conservative target, suggesting a -30.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALKS Analyst Consensus
ALKS Price Target Range
Latest ALKS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALKS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2024 | Mizuho | Uy Ear | Outperform | Maintains | $40.00 |
| Nov 5, 2024 | Stifel | Paul Matteis | Buy | Upgrade | $36.00 |
| Oct 25, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $37.00 |
| Oct 25, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Maintains | $43.00 |
| Oct 25, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $37.00 |
| Oct 25, 2024 | JP Morgan | Jessica Fye | Neutral | Maintains | $26.00 |
| Oct 25, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $30.00 |
| Oct 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $37.00 |
| Oct 10, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $48.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $48.00 |
| Jul 25, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $48.00 |
| Jul 25, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Maintains | $37.00 |
| Jul 25, 2024 | JP Morgan | Jessica Fye | Neutral | Maintains | $32.00 |
| Jul 25, 2024 | Baird | Joel Beatty | Outperform | Maintains | $38.00 |
| Jul 15, 2024 | JP Morgan | Jessica Fye | Neutral | Maintains | $31.00 |
| Jun 17, 2024 | TD Cowen | Joseph Thome | Buy | Initiates | $34.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $35.00 |
| May 23, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Maintains | $48.00 |
| May 2, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $35.00 |
| Apr 19, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $35.00 |
Stocks Similar to Alkermes PLC
The following stocks are similar to Alkermes based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alkermes PLC (ALKS) Financial Data
Alkermes PLC has a market capitalization of $4.87B with a P/E ratio of 13.1x. The company generates $1.51B in trailing twelve-month revenue with a 22.1% profit margin.
Revenue growth is -0.7% quarter-over-quarter, while maintaining an operating margin of +27.7% and return on equity of +29.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Alkermes PLC (ALKS) Company Overview
About Alkermes PLC
Develops biopharmaceutical products for unmet medical needs.
Alkermes plc generates revenue through the commercialization of its proprietary pharmaceutical products aimed at treating various mental health and addiction disorders. The company also engages in collaborations with other pharmaceutical entities, providing technology platforms and leveraging partnerships to enhance its product development capabilities.
With a strong portfolio that includes treatments for schizophrenia, alcohol dependence, and opioid dependence, Alkermes is positioned in the biopharmaceutical industry to address significant health challenges. The company has a presence in the United States and internationally, and its ongoing commitment to research and development indicates potential for future growth through a pipeline of innovative therapies.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,100
CEO
Mr. Richard F. Pops
Country
Ireland
IPO Year
1991
Website
www.alkermes.comAlkermes PLC (ALKS) Latest News & Analysis
Alkermes plc CEO Richard Pops will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, as announced on January 2, 2025.
Alkermes' CEO will present at a major healthcare conference, likely impacting stock performance and investor sentiment based on updates about company strategy and potential developments.
Alkermes plc (Nasdaq: ALKS) will present at the 7th Annual Evercore ISI HealthCONx Conference on Dec. 3, 2024, at 10:25 a.m.
Alkermes' participation in investor conferences can signal potential growth opportunities and increased visibility, impacting investor sentiment and stock performance.
Alkermes has transitioned to proprietary product sales, seeing growth in Lybalvi, Vivitrol, and Aristada. It has $908.9M in liquidity and $73.3M positive cash flow, supporting R&D for ALKS 2680 in a $7.3B market.
Alkermes' transition to proprietary sales and strong product growth, coupled with robust liquidity and positive cash flow, enhances its financial stability and growth potential in a lucrative market.
Alkermes plc (Nasdaq: ALKS) will participate in the Stifel Healthcare Conference on Nov. 18, 2024, at 8:35 a.m., according to a company announcement.
Alkermes' participation in investor conferences can signal potential updates on company performance or product developments, influencing investor sentiment and stock price movements.
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
2 months agoAlkermes plc presented research on its products LYBALVI® and ARISTADA® at recent conferences, highlighting healthcare utilization in schizophrenia and bipolar disorder, and progress on ALKS 2680 for narcolepsy.
Alkermes' research presentations on LYBALVI® and ARISTADA® highlight its innovation in psychiatry, potentially influencing market perception and stock performance based on product efficacy and future sales.
ALKS reported weaker-than-expected Q3 2024 results, despite a year-over-year increase in net sales of proprietary products.
Weaker-than-expected results may indicate operational challenges, but year-over-year sales growth suggests potential for recovery, impacting future earnings and stock performance.
Frequently Asked Questions About ALKS Stock
What is Alkermes PLC's (ALKS) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, Alkermes PLC (ALKS) has a median price target of $36.00. The highest price target is $43.00 and the lowest is $21.00.
Is ALKS stock a good investment in 2025?
According to current analyst ratings, ALKS has 9 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $30.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ALKS stock?
Wall Street analysts predict ALKS stock could reach $36.00 in the next 12 months. This represents a 19.2% increase from the current price of $30.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alkermes PLC's business model?
Alkermes plc generates revenue through the commercialization of its proprietary pharmaceutical products aimed at treating various mental health and addiction disorders. The company also engages in collaborations with other pharmaceutical entities, providing technology platforms and leveraging partnerships to enhance its product development capabilities.
What is the highest forecasted price for ALKS Alkermes PLC?
The highest price target for ALKS is $43.00 from Charles Duncan at Cantor Fitzgerald, which represents a 42.3% increase from the current price of $30.21.
What is the lowest forecasted price for ALKS Alkermes PLC?
The lowest price target for ALKS is $21.00 from Cory Kasimov at JP Morgan, which represents a -30.5% decrease from the current price of $30.21.
What is the overall ALKS consensus from analysts for Alkermes PLC?
The overall analyst consensus for ALKS is bullish. Out of 20 Wall Street analysts, 9 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $36.00.
How accurate are ALKS stock price projections?
Stock price projections, including those for Alkermes PLC, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
